INNT
TOTAL INVALIDATION PROCESSED BY THE IB
30/11/2025
Voltar para busca
Dado oficial do USPTO
HALIODX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
HALIODX
ST13
US500000079188392Classe
5, 9, 10, 44
Pedido
79188392
Registro
5435316
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
01/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 10, 44
Data de depósito
25/02/2016
Data de registro
03/04/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/10/2024
Última transação
01/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
RICHARDS, LESLIE
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Veracyte
HalioDxInvest
HalioDx
Representantes
Cathleen E. Stadecker Downs Rachlin Martin PLLC
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 10Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products for use in vitro testing for use in the clinical diagnostic and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; chemical preparations for medical and pharmaceutical use for in vitro testing for use in the clinical diagnostic and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; biological reagents for medical use for providing information on diagnostics or identification of biological systemsdiagnosis or prognosis of cancer and assessment of patient's response to anti-cancer treatmentmonitoring and management of anti-cancer treatment; biological reagents for providing information on diagnostics or identification of biological systemsdiagnosis or prognosis of cancer and assessment of patient's response to anti-cancer treatmentmonitoring and management of anti-cancer treatment
Classe 9
Downloadable computer software for use in the clinical diagnostic and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; downloadable software in the nature of a mobile application for use in the clinical diagnostic and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition
Classe 10
Medical apparatus and instrumentsautostainersscannersmedical testing devices and diagnostic apparatus for detectinganalyzing or assessing a cancertumor or equivalent medical condition
Classe 44
Medical analysis servicesin vitro testing services for use in the clinical diagnostic and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; health assessment services; genetic testing for medical purposesin vitro testing services for use in the clinical diagnostic and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
11/11/2025
INPC
INVALIDATION PROCESSED
11/11/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/08/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
18/06/2025
C71T
CANCELLED SECTION 71
18/10/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/04/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/02/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
25/10/2018
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
11/10/2018
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
11/10/2018
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
31/08/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/08/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/07/2018
FIMP
FINAL DISPOSITION PROCESSED
10/07/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/07/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
03/04/2018
GPNX
NOTIFICATION PROCESSED BY IB
03/02/2018
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/01/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/01/2018
PUBO
PUBLISHED FOR OPPOSITION
16/01/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/12/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/12/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/12/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/12/2017
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/12/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/12/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
05/12/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/12/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
05/12/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/12/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/09/2017
GNFR
FINAL REFUSAL E-MAILED
06/09/2017
CNFR
FINAL REFUSAL WRITTEN
06/09/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/07/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/07/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/07/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/02/2017
GNRT
NON-FINAL ACTION E-MAILED
23/02/2017
CNRT
NON-FINAL ACTION WRITTEN
23/02/2017
DOCK
ASSIGNED TO EXAMINER
02/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/02/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/02/2017
ALIE
ASSIGNED TO LIE
26/01/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/01/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/01/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/01/2017
CHLD
CHANGE OF OWNER RECEIVED FROM IB
05/01/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
22/12/2016
RFNT
REFUSAL PROCESSED BY IB
29/07/2016
MAFR
APPLICATION FILING RECEIPT MAILED
12/07/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/07/2016
RFRR
REFUSAL PROCESSED BY MPU
11/07/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/07/2016
CNRT
NON-FINAL ACTION WRITTEN
09/07/2016
DOCK
ASSIGNED TO EXAMINER
08/07/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/07/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/07/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HALIODX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.